Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
about
Methotrexate for high-grade osteosarcoma in children and young adultsMethotrexate for high-grade osteosarcoma in children and young adultsPlatinum-induced hearing loss after treatment for childhood cancerEmerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcomaOsteosarcoma: Current Treatment and a Collaborative Pathway to SuccessUnderstanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease ProgressionChildren's Oncology Group's 2013 blueprint for research: bone tumorsAdvances in the management of osteosarcomaEfficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysisCD271+ osteosarcoma cells display stem-like propertiesGermline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good RThe evolution of systemic therapy in sarcoma.Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumorsComparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.A case report of apatinib in treating osteosarcoma with pulmonary metastases.Identification of osteosarcoma-related specific proteins in serum samples using surface-enhanced laser desorption/ionization-time-of-flight mass spectrometry.Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcomaCryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcomaSuppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.Collaborative Pediatric Bone Tumor Program to Improve Access to Specialized Care: An Initiative by the Lebanese Children's Oncology Group.Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogsReview of mifamurtide in the treatment of patients with osteosarcoma.Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase familyKnockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-κB signaling pathway.Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.Immunotherapeutic Intervention against Sarcomas.Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line.Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor StudyCurrent strategies of chemotherapy in osteosarcomaFrequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution.Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma.Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.
P2860
Q24234472-6BD79B7C-D446-42F6-8BB0-DFBBD85CB9EEQ24241431-ADC973CA-59AE-49DC-8BF3-17588F520227Q26470526-18C46504-CC4D-48E4-968A-562867D99932Q26738598-836A6D2A-1C55-4A78-8C4A-23090CD745D3Q26797555-60302750-01A4-44CC-BC70-DEFD107DE85FQ26829949-425AAD59-D2CF-473D-89DA-31432267C231Q27027664-5BF5C29D-7756-4EB6-8A8C-BB8984487ABEQ28067644-55315793-5CDE-41A7-A9FB-D5E0EE4F1DF0Q28084433-7EB584A1-7D73-48D6-9A84-53050C06BF96Q28539288-DD01D2D2-5D3A-4A81-AA05-6DC89A30AC9CQ30235105-953C865B-1F48-492E-8E84-A2DAAE9FD466Q30357731-1EC87771-D3D4-4971-A68B-97AD424442E1Q33274710-E0747573-CC1B-4475-8CC4-96E9861E3333Q33373879-69EEDD36-F901-4F8B-8F58-422717B97547Q33405390-07A36B6D-B501-4349-AF3F-011C9E347115Q33434899-88E1595D-E59A-462A-82B4-08D75A21A452Q33559539-2BDEC0C1-F946-4B60-974C-13479E055945Q33597266-74C8778E-5B4B-40DA-A928-E60BA182A281Q33608263-E3B93963-5821-4266-B9D2-64B9FEA28194Q33624977-706A0D59-5E9C-4EA0-831D-FE6A238C4B92Q33737393-BEE3CA86-AC5F-413A-B5D0-532DAA8DFFB8Q33785368-E5ABCF80-E303-4140-8E29-D76FBFA996E9Q33809324-990472E2-9CAB-47F5-A627-8E828E1F9DD9Q33859567-F499EFFA-B7F5-43DE-9CAA-C8B1422598C8Q33926491-61D82247-3DFC-4C54-82A8-E54F05D7A284Q33947618-A5302500-52B2-4060-8BD0-515BEC177391Q33948137-8AAAE8A8-6795-4E45-A43E-5DB7078DF004Q34029070-54241B88-30C8-4160-AF3C-19B42AE64644Q34070374-867DB705-6590-46DD-927A-3B81E704F882Q34196481-B4348F83-4309-4A52-BF47-C06C041AC55AQ34220071-20D9DA1C-94C3-403F-8045-31D5C94BFA21Q34413741-9D3080BB-38D2-4CD7-83E6-64E61272C0E8Q34511099-E758CBE4-7B13-4686-8400-BE081413DDA7Q34569791-C2AE4169-C1CA-40B6-B9B7-A80D96F1BEA0Q34570006-FCD26BA4-B321-4FF0-83E7-D0CB33991B10Q34588395-8E727979-10BB-4C87-B2D2-A4FE6DE9AD3BQ34588488-1DF6398A-0AE7-4AFC-96DE-6F8C8D3135E8Q34589401-EE11FBAD-F6FF-4AE4-9CD7-DF9BA8E86881Q34619410-BC1BA86D-92C7-4E8E-B4C0-E27FAE7FD04EQ34627906-8AFCCBA1-E1C6-4E0D-B51C-C7FDD88E570D
P2860
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@ast
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@en
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@nl
type
label
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@ast
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@en
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@nl
prefLabel
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@ast
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@en
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@nl
P2093
P356
P1476
Osteosarcoma: a randomized, pr ...... n, and high-dose methotrexate.
@en
P2093
Allen M Goorin
Andrew Huvos
Cindy L Schwartz
Donna Betcher
Ernest Conrad
Eugenie S Kleinerman
Gene Siegal
Helen Nadel
Holcombe Grier
John Healey
P304
P356
10.1200/JCO.2005.06.031
P407
P577
2005-03-01T00:00:00Z